Landscape of human antibody recognition of the SARS-CoV-2 receptor binding domain.
Potent neutralizing monoclonal antibodies are one of the few agents currently available to treat COVID-19. SARS-CoV-2 variants of concern (VOCs) that carry multiple mutations in the viral spike protein can exhibit neutralization resistance, potentially affecting the effectiveness of some antibody-based therapeutics. Here, the generation of a diverse panel of 91 ... human, neutralizing monoclonal antibodies provides an in-depth structural and phenotypic definition of receptor binding domain (RBD) antigenic sites on the viral spike. These RBD antibodies ameliorate SARS-CoV-2 infection in mice and hamster models in a dose-dependent manner and in proportion to in vitro, neutralizing potency. Assessing the effect of mutations in the spike protein on antibody recognition and neutralization highlights both potent single antibodies and stereotypic classes of antibodies that are unaffected by currently circulating VOCs, such as B.1.351 and P.1. These neutralizing monoclonal antibodies and others that bind analogous epitopes represent potentially useful future anti-SARS-CoV-2 therapeutics.
Mesh Terms:
Angiotensin-Converting Enzyme 2, Animals, Antibodies, Monoclonal, Antibodies, Neutralizing, Antibodies, Viral, COVID-19, Cricetinae, Cryoelectron Microscopy, Epitopes, Female, Humans, Male, Mice, Mice, Inbred C57BL, Middle Aged, Neutralization Tests, Protein Binding, Receptors, Virus, SARS-CoV-2, Spike Glycoprotein, Coronavirus
Angiotensin-Converting Enzyme 2, Animals, Antibodies, Monoclonal, Antibodies, Neutralizing, Antibodies, Viral, COVID-19, Cricetinae, Cryoelectron Microscopy, Epitopes, Female, Humans, Male, Mice, Mice, Inbred C57BL, Middle Aged, Neutralization Tests, Protein Binding, Receptors, Virus, SARS-CoV-2, Spike Glycoprotein, Coronavirus
Cell Rep
Date: Oct. 12, 2021
PubMed ID: 34610292
View in: Pubmed Google Scholar
Download Curated Data For This Publication
246784
Switch View:
- Interactions 2